Federica Genovese1, Peter Boor2, Marios Papasotiriou3, Diana J Leeming1, Morten A Karsdal1, Jürgen Floege4. 1. Nordic Bioscience, Herlev, Denmark. 2. Nephrology and Immunology, RWTH University of Aachen, Aachen, NRW, Germany Institute of Pathology, RWTH University of Aachen, Aachen, NRW, Germany Institute of Molecular Biomedicine, Comenius University, Bratislava, Slovakia. 3. Nephrology and Immunology, RWTH University of Aachen, Aachen, NRW, Germany Institute of Pathology, RWTH University of Aachen, Aachen, NRW, Germany Department of Nephrology, University Hospital of Patras, Patras, Greece. 4. Nephrology and Immunology, RWTH University of Aachen, Aachen, NRW, Germany.
Abstract
BACKGROUND: Renal fibrosis is the hallmark of progression to end-stage kidney disease. Non-invasive biomarkers of renal fibrosis could serve as specific end points in clinical trials and improve monitoring and stratification of patients with chronic kidney disease (CKD). To address this, we measured markers of collagen type III turnover in urine and serum of IgA nephropathy (IgAN) patients. METHODS: We measured the collagen type III pro-peptide (Pro-C3), representing production, and a neo-epitope fragment (C3M), representing a specific degradation fragment of collagen type III, in urine and serum samples from two cohorts of IgAN patients using newly developed enzyme-linked immunosorbent assays. RESULTS: With increasing CKD stage, urinary C3M gradually decreased (mean C3M/creatinine: 17.3 ng/mg in CKD stage 1, 3.5 ng/mg in CKD stage 5) whereas urinary Pro-C3 gradually increased (mean Pro-C3/creatinine: 4.1 ng/mg in CKD stage 1, 20.8 ng/mg in CKD stage 5). The urinary Pro-C3/C3M ratio, a measure of collagen type III turnover, significantly increased in advanced CKD stages. Serum C3M was not related to CKD stage but was associated with microinflammation. Urinary C3M was significantly lower in patients whose CKD stage subsequently progressed compared with those who did not progress. CONCLUSIONS: Our results suggest that the combination of urinary markers of collagen type III turnover, in particular the urinary Pro-C3/C3M ratio, is a potential novel, non-invasive diagnostic and prognostic tool to specifically monitor extracellular matrix (ECM) remodelling in kidney fibrosis.
BACKGROUND:Renal fibrosis is the hallmark of progression to end-stage kidney disease. Non-invasive biomarkers of renal fibrosis could serve as specific end points in clinical trials and improve monitoring and stratification of patients with chronic kidney disease (CKD). To address this, we measured markers of collagen type III turnover in urine and serum of IgA nephropathy (IgAN) patients. METHODS: We measured the collagen type III pro-peptide (Pro-C3), representing production, and a neo-epitope fragment (C3M), representing a specific degradation fragment of collagen type III, in urine and serum samples from two cohorts of IgANpatients using newly developed enzyme-linked immunosorbent assays. RESULTS: With increasing CKD stage, urinary C3M gradually decreased (mean C3M/creatinine: 17.3 ng/mg in CKD stage 1, 3.5 ng/mg in CKD stage 5) whereas urinary Pro-C3 gradually increased (mean Pro-C3/creatinine: 4.1 ng/mg in CKD stage 1, 20.8 ng/mg in CKD stage 5). The urinary Pro-C3/C3M ratio, a measure of collagen type III turnover, significantly increased in advanced CKD stages. Serum C3M was not related to CKD stage but was associated with microinflammation. Urinary C3M was significantly lower in patients whose CKD stage subsequently progressed compared with those who did not progress. CONCLUSIONS: Our results suggest that the combination of urinary markers of collagen type III turnover, in particular the urinary Pro-C3/C3M ratio, is a potential novel, non-invasive diagnostic and prognostic tool to specifically monitor extracellular matrix (ECM) remodelling in kidney fibrosis.
Authors: Qinxue Sun; Maike Baues; Barbara M Klinkhammer; Josef Ehling; Sonja Djudjaj; Natascha I Drude; Christoph Daniel; Kerstin Amann; Rafael Kramann; Hyojin Kim; Julio Saez-Rodriguez; Ralf Weiskirchen; David C Onthank; Rene M Botnar; Fabian Kiessling; Jürgen Floege; Twan Lammers; Peter Boor Journal: Sci Transl Med Date: 2019-04-03 Impact factor: 17.956
Authors: Federica Genovese; Ahmad Akhgar; Sung Sam Lim; Alton B Farris; Monica Battle; Jason Cobb; Dominic Sinibaldi; Morten A Karsdal; Wendy I White Journal: Kidney360 Date: 2021-06-18
Authors: Michael Praktiknjo; Jennifer Lehmann; Mette J Nielsen; Robert Schierwagen; Frank E Uschner; Carsten Meyer; Daniel Thomas; Christian P Strassburg; Flemming Bendtsen; Søren Møller; Aleksander Krag; Morten A Karsdal; Diana J Leeming; Jonel Trebicka Journal: Hepatol Commun Date: 2018-01-18
Authors: Ryanne S Hijmans; Daniel Guldager Kring Rasmussen; Saleh Yazdani; Gerjan Navis; Harry van Goor; Morten Asser Karsdal; Federica Genovese; Jacob van den Born Journal: J Transl Med Date: 2017-03-20 Impact factor: 5.531
Authors: Elisabeth G D Stribos; Signe Holm Nielsen; Susanne Brix; Morten Asser Karsdal; Marc A Seelen; Harry van Goor; Stephan J L Bakker; Peter Olinga; Henricus A M Mutsaers; Federica Genovese Journal: PLoS One Date: 2017-04-21 Impact factor: 3.240